Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Hartford HealthCare Teams with Cadence to Deploy AI Remote Care for Seniors
Hartford HealthCare announced a partnership with Cadence to embed AI‑driven vitals monitoring and lifestyle coaching into a new remote‑care program for seniors with chronic illnesses. The collaboration will let clinicians review daily health data and intervene between visits, aiming to keep patients safely at home while improving outcomes.
4basebio Announces Lease of an Innovation Hub and Manufacturing Facility in Cambridge, UK
4basebio PLC announced a lease for a 26,500 sq ft innovation hub and manufacturing facility in Cambridge, UK, slated to open in late summer 2026. The site will feature 7,500 sq ft of specialized laboratory space with 15 labs, advanced biosafety equipment, and a...
School With 50 Locations Uses Electric Shock Devices on Autistic Children — the FDA Wants to Ban the Devices
The U.S. Food and Drug Administration has issued a proposal to ban electric shock devices used to curb self‑injurious and aggressive behavior in individuals with developmental disabilities, including autistic children. The only U.S. institution still employing the aversive therapy is...
Why Nurses Learn More From Fake Patients Than Textbooks
Simulation‑based learning is reshaping nursing education by giving students a safe arena to practice life‑or‑death decisions. Repeated high‑fidelity scenarios improve real‑time judgment, pattern recognition, and teamwork more than textbook study alone. Evidence shows nurses who train in simulated environments make...
Highmark Health Names Heather Cianfrocco as New COO to Drive Living Health Strategy
Highmark Health appointed Heather Cianfrocco, former UnitedHealth Group executive, as chief operating officer. The move is intended to accelerate the company's Living Health strategy and address fragmentation in the U.S. health‑care system.
Calla Lily Clinical Care Doses First Patients in Clinical Trial for Intravaginal Drug Delivery Platform for Threatened Miscarriage
Calla Lily Clinical Care has begun dosing the first participants in the FREEDOM clinical trial, testing its 400 mg intravaginal progesterone product Callavid. The NIHR‑funded study targets women with luteal phase insufficiency, a condition linked to threatened miscarriage and infertility. Callavid’s...
Haleon Appoints Richard Manso as U.S. CMO to Accelerate Data‑Driven Health Marketing
Haleon has named former Google executive Richard Manso as its U.S. chief marketing officer. Manso will steer an integrated, data‑focused marketing strategy across categories, targeting moments when consumers make health decisions. The move signals Haleon's push to deepen personalization and...
CellCentric Raises $220M to Get Multiple Myeloma Pill to Market
CellCentric, a 22‑year‑old transatlantic biotech, closed a $220 million Series D round to accelerate development of its oral multiple myeloma drug. The capital will fund the completion of Phase III trials, scale manufacturing, and prepare regulatory filings. The therapy is designed for patients...
How Valvoline Is Driving Mental Health Support with Ronald McDonald House
Valvoline Inc. pledged $750,000 over three years to fund behavioral‑health services at Ronald McDonald House, directing $25,000 each year to ten chapters for counseling, therapy and crisis care. The partnership also launches a store‑wide donation drive through May 31, allowing customers to add...
Bayer to Buy Perfuse Therapeutics for $300M Upfront
Bayer announced a $300 million upfront payment to acquire ophthalmology biotech Perfuse Therapeutics, securing its mid‑stage program aimed at the leading causes of blindness. The transaction represents Bayer’s first pharmaceutical merger‑and‑acquisition in several years, signaling a renewed focus on specialty eye...
Repeat Visits Signal Missed Diagnoses, Not Anxiety
The patient who keeps coming back is the patient you have not figured out yet. A pediatrician in her forties learned that the hard way. She walked into the ER with blood pressures in the 200s and was told anyone...
DDW Highlights: 6 May 2026
In this episode, Bruno Quinney highlights a surge in UK biotech financing, noting £552 million ($746 million) in Q1 2026 equity funding and the UK's capture of 57% of European biotech venture capital. He also covers the UK’s sweeping clinical‑trial reforms aimed at...
UnitedHealthcare Cuts Prior Authorization for 30% of Services, Aiming to Ease Care Access
UnitedHealthcare announced it will drop prior‑authorization requirements for 30% of its covered services, targeting outpatient surgeries, certain diagnostics and therapies. The move, part of a broader simplification push, could affect 257 million members and pressure rivals to follow suit.
PharmaShots Awards 2026: Honoring Global Market Titans & Healthcare Innovators
The PharmaShots Awards 2026 celebrated global healthcare innovation, recognizing excellence across biopharma, medtech, diagnostics, generics, nutraceuticals, animal health, digital health, and AI‑driven drug discovery. High‑profile companies such as Eli Lilly, Pfizer, AbbVie, Medtronic, Johnson & Johnson, Roche and XtalPi were among the honorees....
Aging Population Drives Costs; Reform or Raise Taxes
I find this stuff pretty silly. The spending isn’t “the state”. It’s us. It’s the demographics of an aging population and the impact of that on the triple lock, social care and the NHS. We reform these or we pay more...
GEODIS to Enhance Its Pharmaceutical Logistics Capabilities
GEODIS is opening a temperature‑controlled, GDP‑compliant pharmaceutical warehouse near Manchester Airport, slated to start operations on June 1, 2026. The 2,000‑pallet facility offers controlled‑room, chilled, and potential frozen zones, plus returns areas and 24/7 temperature monitoring. Its location near the M6, M62...
CVS Profits Eclipse $2.9 Billion As Aetna Health Plan Costs Ease
CVS Health reported first‑quarter net income of $2.96 billion, a 66% jump from a year ago, as its Aetna health‑plan costs eased. The medical‑benefit ratio fell to 84.6%, below the prior‑year 87.3%, boosting profitability. Total revenue rose 6% to $100.4 billion, with...
Signadori Bio Raises €11M to Advance Tumour Platform
Signadori Bio announced an €11 million ($11.9 million) seed extension to fund its in‑vivo monocyte engineering platform for solid tumours. The Series A round, led by Taiho Ventures with Sofinnova and Invivo Partners, will support lead candidate nomination, platform refinement, and team expansion...
Novo Nordisk's Q1 in Four Words: Pills, Pricing, Payments and Pressure
Novo Nordisk’s first‑quarter performance centered on its obesity drug Wegovy, which now serves roughly one million patients in the United States. The company is navigating heightened pricing pressure as insurers push for larger rebates while regulators scrutinize the drug’s cost....
Pharmaceutical Packaging Summit 2026 | June 22-23 | Encore Boston Harbor, Boston, MA
The Pharmaceutical Packaging Summit 2026 will convene senior pharma packaging leaders and solution providers at Encore Boston Harbor on June 22‑23. The invitation‑only forum will address regulatory serialization, patient‑centric design, sustainability, smart packaging, supply‑chain resilience, and cost‑efficient innovation. Attendees will...
Most Atraumatic Rotator Cuff Tears Heal Without Surgery
I struck a nerve yesterday... A note for those who don't read the entire article. As some ortho colleagues noted... There is a lot of nuance involved. And that's the point to get across. Far too many...
FDA Approves Incyte’s Once‑Daily Jakafi XR for Myelofibrosis, Polycythemia Vera and GVHD
The U.S. FDA has approved Incyte’s Jakafi XR, a once‑daily extended‑release ruxolitinib tablet, for adults with intermediate‑ or high‑risk myelofibrosis, polycythemia vera patients who cannot use hydroxyurea, and patients 12 years and older with certain graft‑versus‑host disease forms. The decision follows...
The Imperative for Equity in Obesity Care Is Alive and Well
At the ASMBS Annual Meeting, leaders highlighted that breakthroughs in metabolic surgery and anti‑obesity medications are undermined by stark inequities in access. Only a small fraction of eligible patients receive surgery, while high out‑of‑pocket costs keep new drugs out of...
From Insight to Impact: Making Real-World Evidence Actionable in Urology
Real‑world evidence (RWE) is reshaping urology, but fragmented, unstructured data limits its impact on everyday clinical decisions. In non‑muscle invasive bladder cancer, real‑world datasets reveal wide variation in BCG maintenance and treatment sequencing, while prostate cancer diagnostics suffer from inconsistent...
RFK Jr. Clears Path for Minors' Use of Tanning Beds, Much to the Dismay of Dermatologists
Future Health and Human Services Secretary‑designate Robert F. Kennedy Jr. withdrew the FDA’s proposed rule that would have barred minors from indoor tanning salons and required all users to sign a cancer‑risk acknowledgment. The rule, first drafted in 2015, aimed to curb exposure...
Why Healthcare Costs Keep Climbing
In this brief episode, Dr. Pearl discusses how generative AI can empower patients and clinicians by providing instant, personalized health insights before a doctor's visit, illustrated with a real‑world example of a skier diagnosing a rotator cuff tear via ChatGPT....
Diagnostic Dilemma: A Woman Turned Black and Blue Weeks After Starting a New Medication
A 68‑year‑old U.S. woman developed extensive blue‑gray to black patches on her arms and legs within two weeks of starting a daily 100‑mg dose of minocycline for rosacea. Doctors diagnosed type II minocycline‑induced hyperpigmentation, a side effect that typically appears after...
Abortion Pill Fight Thrust Into Spotlight as Midterms Heat Up
The Supreme Court temporarily reinstated mail‑order access to the abortion pill mifepristone after a federal appeals court barred telehealth prescriptions, reigniting a national legal battle. Justice Samuel Alito’s one‑week order follows a broader fight over medication abortion that intensified after...
Can Mammals Regrow Lost Limbs? This New Treatment Could Be the First Step
Researchers at Texas A&M have demonstrated that a two‑step treatment using growth factors FGF2 and BMP2 can trigger partial digit regeneration in mice. The protocol first applies FGF2 to create a blastema‑like cell mass, then adds BMP2 to drive bone...
Understanding Potential Ocular Side Effects of Injectable GLP-1 Medications
Recent research suggests a rare but serious link between the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) and non-arteritic anterior ischemic optic neuropathy (NAION), a form of eye stroke that can cause permanent vision loss. A 2026 JAMA Network Open study...
Doctors' Growing AI Deepfakes Problem
AI-generated deepfake videos are impersonating physicians to market dubious supplements and medical devices, prompting the American Medical Association to call for new privacy and identity‑protection laws. States such as California and Pennsylvania are already moving toward disclosure mandates and bans...
Why Recovery After a Hip Fracture Is About More than Bones
Recent research in *Age and Ageing* and the *Australasian Journal on Ageing* shows that recovery after a hip fracture is driven as much by cultural beliefs, family expectations, and daily life realities as by surgical care. Only about half of...
Winners Announced at Medilink Healthcare Business Awards
The Medilink North of England Healthcare Business Awards 2026 returned to Sheffield’s Cutlers’ Hall, marking the association’s 30‑year anniversary. Nearly 300 delegates gathered to honor achievements across medical technology, digital health, sustainability and NHS partnerships. Winners included Mitotype Precision Labs,...
There Is No Evidence You Should Reapply Sunscreen Every 2 Hours.
The article dismantles the FDA’s two‑hour sunscreen reapplication rule, showing it rests on weak epidemiological surveys and circular citations rather than solid science. It traces the guideline’s origin to a 2007 proposed rule and highlights that the studies FDA cites...
The Billion-Dollar Women’s Health Market Driving A New Endometriosis Focus
The GLP‑1 drug class, now projected to generate over $100 billion a year, is attracting pharmaceutical interest in endometriosis—a condition that impacts roughly 190 million women worldwide. Companies such as Novo Nordisk and Eli Lilly are testing the anti‑inflammatory effects of Ozempic, Wegovy...
Sickle Cell Disease After Casgevy: Seven Companies to Watch in 2026
Casgevy’s $2.2 million, ex vivo CRISPR cure proved sickle cell disease can be edited at its genetic root, but its complex manufacturing and conditioning limit broad access. In response, a wave of innovators is targeting simpler, safer, and more scalable solutions—from Beam’s...
HTN Now Panel Share Their Learnings, Experiences, and Insights with Ambient Voice Technology
A panel of senior clinicians from The Dudley Group, Sandwell and West Birmingham and the University Hospitals of Northamptonshire and Leicester discussed their ambient voice technology (AVT) pilots. Both organisations progressed from early 2024 research to multi‑supplier pilots in 2025,...
Cytospire Therapeutics Secures £61m to Advance Cancer Treatment
Cytospire Therapeutics, a UK biotech, closed a £61 million (≈$77 million) Series A round to accelerate its multispecific engager antibody platform. The capital will fund the development of its lead candidate, CYT X300, aimed at EGFR‑positive solid tumours such as colorectal, head‑and‑neck and non‑small‑cell...
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
Starting July 2026, Medicare will launch a short‑term GLP‑1 Bridge pilot that covers weight‑loss drugs such as Wegovy, Zepbound and Foundayo for a flat $50 monthly copayment. The benefit is limited to beneficiaries enrolled in a Part D plan who meet...
Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support
The White House released a 195‑page National Drug Control Strategy that touts easier access to treatment, prevention programs, and new technologies like AI‑driven drug screening. While the plan’s public‑health goals align with experts, the Trump administration simultaneously pursues massive federal...
Antwerp Startup Maurice & Nora Raises €1M to Address Rising Care Demand
Antwerp‑based social‑impact startup Maurice & Nora secured €1 million (about $1.09 million) in a funding round led by Coformaco and a roster of angel investors. The capital will fund commercial expansion, AI‑driven matching technology, and team growth as the platform scales its...
Hospitals Sue Anthem over Policy Prohibiting Use of Out-of-Network Radiologists
California hospitals have filed a lawsuit against Anthem, challenging a new policy that will levy a 10% administrative penalty on claims involving out‑of‑network radiologists and other physicians starting June 1. The hospitals argue the policy breaches California’s AB 72, which permits...
Medtronic’s VitalFlow Transport Frame AG Gains CE Mark
Medtronic has earned a CE mark for its VitalFlow Transport Frame Air and Ground (AG), an accessory that lets the full ECMO system be moved safely by ambulance, fixed‑wing, or rotary aircraft. The certification clears the frame for inter‑hospital transfers...
American College of Radiology Council Approves ‘Groundbreaking’ Framework for Assessing AI
The American College of Radiology (ACR) Council approved a new Practice Parameter for Imaging Artificial Intelligence, a framework designed to guide real‑world AI deployment in radiology. Developed with the Society for Imaging Informatics in Medicine, the guideline outlines governance, inventory,...
Cervical Cancer Gap Will Widen without Urgent Global Action
A new Lancet modelling study warns that without accelerated HPV vaccination and screening, cervical‑cancer disparities between low‑ and middle‑income countries (LMICs) and high‑income countries (HICs) will widen dramatically. Currently only 10% of women in LMICs are screened and 23% of...
Exercise Physiologists Demand an End to 'Discriminatory' Health Tax
Exercise and Sports Science Australia (ESSA) has launched an "axe the tax" campaign to eliminate the 10% Goods and Services Tax (GST) applied to exercise physiology services, a levy that other allied health professions do not face. The peak body...
Beyond Telesurgery: How Proximie Uses AI to Optimise Surgery Logistics
Proximie, an AWS‑partner, is turning operating‑room logistics into a data‑driven system by deploying ceiling‑mounted computer‑vision sensors and a hybrid edge‑to‑cloud architecture that handles 120 TB of video. The platform uses generative AI to predict procedure duration, enabling hospitals like St Thomas’ to...
Furin‐Mediated Intracellular Aggregation of Radioactive Molecules for Enhanced Radionuclide Imaging and Tumor Therapy
Researchers have engineered a furin‑responsive radioactive probe, RVRR‑TPE, that self‑assembles into nanoparticles inside furin‑positive cancer cells. The molecule couples a furin‑cleavable Arg‑Val‑Arg‑Arg peptide, an aggregation‑induced emission fluorophore (tetraphenylethene), and a phenol group for iodine‑125/131 labeling. In mouse models, the 125I/131I‑labeled...
Caris Launches Caris MI Clarity for AI-Powered Breast Cancer Recurrence Risk Assessment
Caris Life Sciences has introduced Caris MI Clarity, an AI‑driven prognostic test that evaluates both early (0‑5 years) and late (5‑15 years) distant recurrence risk for postmenopausal patients with HR‑positive/HER2‑negative, node‑negative early‑stage breast cancer. The assay analyzes digitized H&E pathology...
Hierarchically Multifunctional Fiber‐optic Theranostic Probe for Cancer Photothermal‐photodynamic Synergism
Researchers have created a hierarchically multifunctional fiber‑optic probe that simultaneously measures dissolved oxygen and delivers combined photothermal‑photodynamic therapy. The three‑layer architecture isolates an Ru(dpp) oxygen sensor, an ICG photosensitizer, and a CaO2@LA oxygen‑generating layer, eliminating optical crosstalk and counteracting tumor...